Disparities in Prevalence of Key Chronic Diseases by Gender and Race/Ethnicity among Antiretroviral-Treated HIV-Infected Adults in the Us

Abstract

Background

Certain sociodemographic subgroups of HIV-infected patients may experience more chronic disease than others due to behavioural risk factors, advanced HIV disease or complications from extended use of combination antiretroviral therapy (cART), but recent comparative data are limited.

Methods

We studied HIV-infected adult patients in care during 2006–2010 who had been prescribed ≥6 months of cART. We analysed the prevalence of selected key chronic conditions and polymorbidity (having 2 or more out of 10 key conditions) by gender and race/ethnicity.

Results

Of the 3,166 HIV-infected patients (median age 47 years, CD4⁺ T-cell count 496 cells/mm³, duration of cART use 6.8 years), 21% were female, 57% were non-Hispanic White and over half were current or former tobacco smokers. The five most frequent conditions among women (median age 45 years) were dyslipidaemia (67.3%), hypertension (57.4%), obesity (31.7%), viral hepatitis B or C coinfection (29.0%) and low high-density lipoprotein cholesterol (HDLc; 27.3%). The five most frequent conditions in men (median age 47 years) were dyslipidaemia (81.2%), hypertension (54.4%), low HDLc (41.1%), elevated triglycerides (32.3%) and elevated non-HDLc (26.8%). In multivariable analyses, Hispanic patients had higher prevalence of obesity and diabetes than White patients; Black patients had higher prevalence of obesity and hypertension but lower rates of lipid abnormalities. Of all patients, 73.7% of women and 66.8% of men had polymorbidity, with no evidence of disparities by race/ethnicity.

Conclusions

Among contemporary cART-treated HIV-infected adults, chronic conditions and polymorbidity were common, underscoring the importance of chronic disease prevention and management among ageing HIV-infected patients.

References

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293–299.

Bhaskaran

, Hamouda

, Sannes

Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51–59.

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860.

Buchacz

, Baker

R.K.

, Palella

F.J.

AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24: 1549–1559.

Ferry

, Raff

, Collin-Filleul

Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51: 407–415.

Deeks

S.G.

, Phillips

A.N.

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.

Goulet

J.L.

, Fultz

S.L.

, Rimland

Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?

Clin Infect Dis 2007; 45: 1593–1601.

Moore

R.D.

, Gebo

K.A.

, Lucas

G.M.

, Keruly

J.C.

Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47: 1102–1104.

Mocroft

, Reiss

, Gasiorowski

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55: 262–270.

10.

French

A.L.

, Gawel

S.H.

, Hershow

Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51: 399–406.

11.

Önen

N.F.

, Overton

E.T.

, Seyfried

Aging and HIV Infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11: 100–109.

12.

Kingsley

L.A.

, Cuervo-Rojas

, Munoz

Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 2008; 22: 1589–1599.

13.

Lucas

G.M.

, Mehta

S.H.

, Atta

M.G.

End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007; 21: 2435–2443.

14.

Mocroft

, Kirk

, Gatell

Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119–1127.

15.

Spradling

P.R.

, Richardson

J.T.

, Buchacz

Trends in hepatitis C virus infection among patients in the HIV outpatient study, 1996–2007. J Acquir Immune Defic Syndr 2010; 53: 388–396.

16.

Kovari

, Ledergerber

, Battegay

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50: 502–511.

17.

Calmy

, Fux

C.A.

, Norris

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200: 1746–1754.

18.

Arnsten

J.H.

, Freeman

, Howard

A.A.

, Floris-Moore

, Lo

Y.T.

, Klein

R.S.

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617–623.

19.

Worm

S.W.

, De Wit

, Weber

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009; 119: 805–811.

20.

Neuhaus

, Jacobs

D.R.

, Baker

J.V.

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788–1795.

21.

Wand

, Calmy

, Carey

D.L.

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445–2453.

22.

Crum-Cianflone

, Huppler Hullisiek

, Marconi

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral theraphy: a 20-year cohort study. AIDS 2009; 23: 41–50.

23.

Patel

, Hanson

D.L.

, Sullivan

P.S.

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148: 728–736.

24.

Palella

F.J.

Jr. , Baker

R.K.

, Moorman

A.C.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.

25.

Buchacz

, Baker

R.K.

, Moorman

A.C.

Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS 2008; 22: 1345–1354.

26.

Deeks

S.G.

Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17: 118–123.

27.

Lau

, Gange

S.J.

, Moore

R.D.

Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44: 179–187.

28.

DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723–1735.

29.

Carr

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17: S141–S148.

30.

Anastos

, Lu

, Shi

Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007; 45: 34–42.

31.

Hessol

N.A.

, Kalinowski

, Benning

Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007; 44: 287–294.

32.

Lichtenstein

K.A.

, Armon

, Buchacz

Low CD4(+) T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435–447.

33.

Carroll

M.D.

, Lacher

D.A.

, Sorlie

P.D.

Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773–1781.

34.

Ogden

C.L.

, Carroll

M.D.

, Curtin

L.R.

, McDowell

M.A.

, Tabak

C.J.

, Flegal

K.M.

Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549–1555.

35.

Cutler

J.A.

, Sorlie

P.D.

, Wolz

, Thom

, Fields

L.E.

, Roccella

E.J.

Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988– 1994 and 1999-2004. Hypertension 2008; 52: 818–827.

36.

Kramer

, Han

, Post

Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens 2004; 17: 963–970.

37.

Danaei

, Ding

E.L.

, Mozaffarian

The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009; 6: e1000058.

38.

Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults–United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2003; 52: 833–837.

39.

Coresh

, Selvin

, Stevens

L.A.

Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047.

40.

Guaraldi

, Orlando

, Zona

Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120–1126.

41.

Zou

A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702–706.

42.

Greenland

Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004; 160: 301–305.

43.

Amorosa

, Synnestvedt

, Gross

A tale of 2 epidemics – The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39: 557–561.

44.

Brown

T.T.

, Chu

, Wang

Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007; 21: 1731–1738.

45.

Boodram

, Plankey

M.W.

, Cox

Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS 2009; 23: 1009–1016.

46.

Ogden

C.L.

Disparities in obesity prevalence in the United States: black women at risk. Am J Clin Nutr 2009; 89: 1001–1002.

47.

Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults – United States, 2003–2010. MMWR Morb Mortal Wkly Rep 2012; 61: 103–108.

48.

Lichtenstein

K.A.

, Delaney

K.M.

, Armon

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48–56.

49.

Mondy

, Overton

E.T.

, Grubb

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44: 726–734.

50.

Longenecker

C.T.

, Scherzer

, Bacchetti

, Lewis

C.E.

, Grunfeld

, Shlipak

M.G.

HIV viremia and changes in kidney function. AIDS 2009; 23: 1089–1096.

51.

DallaPiazza

, Amorosa

V.K.

, Localio

, Kostman

J.R.

, Lo Re

III Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116.

52.

Tien

P.C.

, Choi

A.I.

, Zolopa

A.R.

Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55: 316–322.

53.

Kaplan

R.C.

, Kingsley

L.A.

, Sharrett

A.R.

Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45: 1074–1081.

54.

De Wit

, Sabin

C.A.

, Weber

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224–1229.

55.

SMART Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133–1144.

56.

Aberg

J.A.

, Kaplan

J.E.

, Libman

Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 651–681.

57.

Horberg

M.A.

, Aberg

J.A.

, Cheever

L.W.

, Renner

, Kaleba

E.O.

, Asch

S.M.

Development of National and Multiagency HIV Care Quality Measures. Clin Infect Dis 2010; 51: 732–738.

58.

Lohse

, Gerstoft

, Kronborg

Comorbidity Acquired Before HIV Diagnosis and Mortality in Persons Infected and Uninfected With HIV: A Danish Population-Based Cohort Study. J Acquir Immune Defic Syndr 2011; 57: 334–339.